Shopping Cart

Your shopping cart is currently empty

PF-06260933

Name: PF-06260933
Brand: TargetMol
SKU: T4221
Price: 42 USD
Availability: InStock
Rating: 5 (10 reviews)

🥰Excellent

Catalog No. T4221Cas No. 1811510-56-1

Alias PF-6260933, PF6260933, PF 6260933

PF-06260933 is a highly selective small-molecule MAP4K4 inhibitor with IC50s of 3.7 and 160 nM for kinase and cell, respectively.

PF-06260933

🥰Excellent

Purity: 99.97%

Catalog No. T4221Alias PF-6260933, PF6260933, PF 6260933Cas No. 1811510-56-1

PF-06260933 is a highly selective small-molecule MAP4K4 inhibitor with IC50s of 3.7 and 160 nM for kinase and cell, respectively.

Pack Size	Price	USA Warehouse	Global Warehouse
1 mg	$42	In Stock	In Stock
5 mg	$105	In Stock	In Stock
10 mg	$166	In Stock	In Stock
25 mg	$342	In Stock	In Stock
50 mg	$513	In Stock	In Stock
100 mg	$745	In Stock	In Stock
200 mg	$987	In Stock	In Stock
1 mL x 10 mM (in DMSO)	$105	In Stock	In Stock

Add to Cart

Add to Quotation

In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]

All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.

Questions

Batch Information

Select Batch

Purity:99.97%

Color:White

Resource Download

COA

Product Introduction

Bioactivity

Description	PF-06260933 is a highly selective small-molecule MAP4K4 inhibitor with IC50s of 3.7 and 160 nM for kinase and cell, respectively.
Targets&IC50	MAP4K4:3.7 nM
In vitro	Treatment with PF-06260933 significantly enhances the resistance of human aortic endothelial cells (EC) to TNF-α-induced increases in endothelial permeability in vitro.
In vivo	Treatment with PF-06260933 does not modify plasma lipid content in a mouse model, yet it leads to decreased glucose levels, mirroring outcomes seen in whole-body-inducible Map4k4 knockout animals. Moreover, PF-06260933 administration results in either the attenuation of plaque progression or promotion of plaque regression in this model (46.0% versus 25.5%), alongside reductions in both plasma glucose and lipid content.
Synonyms	PF-6260933, PF6260933, PF 6260933

Chemical Properties

Molecular Weight	296.75
Formula	C₁₆H₁₃ClN₄
Cas No.	1811510-56-1
Smiles	Nc1ccc(cn1)-c1cnc(N)c(c1)-c1ccc(Cl)cc1
Relative Density.	1.330 g/cm3 (Predicted)

Storage & Solubility Information

Storage

In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.

Solubility Information

DMSO: 50 mg/mL (168.49 mM), Sonication is recommended.

In Vivo Formulation

10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (6.74 mM), Sonication is recommended.

Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.

Solution Preparation Table

DMSO

	1mg	5mg	10mg	50mg
1 mM	3.3698 mL	16.8492 mL	33.6984 mL	168.4920 mL
5 mM	0.6740 mL	3.3698 mL	6.7397 mL	33.6984 mL
10 mM	0.3370 mL	1.6849 mL	3.3698 mL	16.8492 mL
20 mM	0.1685 mL	0.8425 mL	1.6849 mL	8.4246 mL
50 mM	0.0674 mL	0.3370 mL	0.6740 mL	3.3698 mL
100 mM	0.0337 mL	0.1685 mL	0.3370 mL	1.6849 mL

Calculator

Molarity Calculator
Dilution Calculator
Reconstitution Calculator
Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:

For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, TargetMol | Animal experiments

and a total of 10 animals are to be administered, using a formulation of TargetMol | reagent

10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH₂O , the resulting working solution concentration would be 2 mg/mL.

Stock Solution Preparation:

Dissolve 2 mg of the compound in 100 μL DMSO TargetMol | reagent to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.

Preparation of the In Vivo Formulation:

1) Add 100 μL of the DMSO TargetMol | reagent stock solution to 400 μL PEG300 and mix thoroughly until the solution becomes clear.

2) Add 50 μL Tween 80 and mix well until fully clarified.

3) Add 450 μL Saline,PBS or ddH₂O TargetMol | reagent and mix thoroughly until a homogeneous solution is obtained.

This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.

All co-solvents required for this protocol, includingDMSO, PEG300/PEG400, Tween 80, SBE-β-CD, and Corn oil, are available for purchase on the TargetMol website.

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc